Topical formulation and use of buspirone

摘要

A liquid or semi-solid topical formulation of buspirone, when applied to human epidermis in vitro (following methods defined herein), results in a transepidermal flux rate of buspirone (individual or mean data) in one or more of the following ranges: 0.1 to 1.1 mug/cm²/hour as assessed over 5 hours following application; 0.09 to 0.60 mug/cm²/hour as assessed over 13 hours following application; 0.09 to 0.48 mug/cm²/hour as assessed over 24 hours following application; 0.08 to 0.46 mug/cm²/hour as assessed over 30 hours following application; and 0.08 to 0.39 mug/cm²/hour as assessed over 48 hours following application. Buspirone is useful for the manufacture of a topical medicament for use in the treatment of pruritus or an immune-related skin disease.